• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: ROCHE DIABETES CARE, INC. ACCU-CHEK SMARTVIEW TEST STRIPS; BLOOD GLUCOSE MONITORING TEST STRIPS

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

ROCHE DIABETES CARE, INC. ACCU-CHEK SMARTVIEW TEST STRIPS; BLOOD GLUCOSE MONITORING TEST STRIPS Back to Search Results
Model Number 06337546001
Device Problem Incorrect, Inadequate or Imprecise Result or Readings (1535)
Patient Problems Hypoglycemia (1912); Sweating (2444)
Event Date 12/09/2020
Event Type  malfunction  
Event Description
It was reported the patient received the following results within 15 minutes: 119 mg/dl and 55 mg/dl.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
ACCU-CHEK SMARTVIEW TEST STRIPS
Type of Device
BLOOD GLUCOSE MONITORING TEST STRIPS
Manufacturer (Section D)
ROCHE DIABETES CARE, INC.
9115 hague road
indianapolis IN 46250 0457
MDR Report Key11055017
MDR Text Key223056640
Report Number3011393376-2020-04584
Device Sequence Number1
Product Code NBW
UDI-Device Identifier00365702493100
UDI-Public00365702493100
Combination Product (y/n)N
PMA/PMN Number
K113137
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type consumer
Type of Report Initial,Followup
Report Date 03/29/2021
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? No
Is this a Product Problem Report? Yes
Device Operator Lay User/Patient
Device Expiration Date11/30/2021
Device Model Number06337546001
Device Catalogue Number06337546001
Device Lot Number479034
Was Device Available for Evaluation? No
Initial Date Manufacturer Received 12/09/2020
Initial Date FDA Received12/22/2020
Supplement Dates Manufacturer Received03/10/2021
Supplement Dates FDA Received03/29/2021
Patient Sequence Number1
Treatment
NOVOLIN N INSULIN; NOVOLIN N INSULIN
Patient Age76 YR
Patient Weight120
-
-